SynCo expands agreement with OncoMed to manufacture cancer stem cell antibodies
SynCo Bio Partners has expanded its current agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells.
Under the expanded agreement, in addition to antibody OMP-21M18, SynCo will fill batches of OncoMed's investigational products, two additional antibodies in the OncoMed pipeline for use in Phase I and II clinical trials.
More information
